Zepbound Injection Schedule Tracker: What to Log and Why
6 min read
CEO & Co-Founder of miora. Consumer health growth expert.
Zepbound is Mounjaro under a different label - same compound, same titration steps - but the user base is different. People on Zepbound are typically running it for weight loss, not diabetes, and the question that drives every tracking decision is whether the protocol is preserving muscle while the weight comes off. This is the schedule and side-effect log built for that question.
Topics on this page
Zepbound is tirzepatide under a different brand. The compound, dose steps, and side-effect profile are identical to Mounjaro; the difference is the indication and the prescriber.
The titration interval is four weeks per step in the standard schedule. Slower is acceptable; faster requires a prescriber decision and usually a tolerance signal that you logged.
Daily protein in grams is the single most actionable metric on Zepbound. Muscle loss is the failure mode and protein is the lever.
Zepbound is tirzepatide for chronic weight management - the same compound as Mounjaro, marketed to a different audience. The pen, the dose steps, and the titration schedule are all functionally identical. What is different is the framing. Mounjaro patients are often tracking glycemic outcomes alongside the weight change; Zepbound patients are tracking the weight change alongside body composition, muscle preservation, and the slow drift in mood and energy that the longer protocols surface. This guide is the schedule plus the side-effect log specifically tuned to the Zepbound-for-weight-loss use case.
The FDA-approved Zepbound titration is one step every four weeks, starting at 2.5 mg and progressing through 5, 7.5, 10, 12.5, and 15 mg. The 2.5 mg starting dose is a build-tolerance step and is not the maintenance dose - most users move off it after four weeks. The 5 mg, 10 mg, and 15 mg steps are the typical maintenance doses depending on tolerance and response.
The titration is not automatic. Each step requires the prescriber to confirm that the previous step was tolerated and that escalating is appropriate. In practice, the conversation is short if the user can produce day-by-day side-effect logs from the previous four weeks; it is longer and more guess-based if the user can only describe the experience verbally.
Variations from standard are common and legitimate. Some users stay at a step longer than four weeks because the side-effect curve has not compressed. Some skip back a step if a new step is producing day-1 nausea above a 4-out-of-5. None of this is in the package insert; all of it requires structured tracking to communicate.
Every titration step on Zepbound produces a side-effect curve that widens for the first week and then compresses across weeks two through four. The compression is the signal that the body has adapted and that the next titration is reasonable. Without daily logging there is no way to see compression; there is only a vague sense of 'feeling better than I did the first week.'
What compression looks like in the data: week one at the new step shows day-1 nausea at 3 or 4, day-2-3 energy dip at -1 from baseline. Week two shows day-1 at 2 or 3, day-2-3 energy near baseline. Week three shows day-1 at 1 or 2, energy normal. By week four, the curve is essentially flat with a mild day-1 reminder.
What no-compression looks like: week one at the new step has day-1 nausea at 4, week two has day-1 at 4, week three still at 4. The curve has not narrowed. This is the data point that tells you and the prescriber that this step may be the ceiling, or that a 4-week hold rather than a step-up is the right call.
The single most actionable daily metric on a Zepbound protocol is protein intake in grams. The mechanism is straightforward: tirzepatide suppresses appetite, total intake drops, and unless the user is deliberately prioritizing protein, the protein number drops alongside everything else. Muscle loss alongside fat loss is the predictable consequence.
The target is roughly 1.6 g/kg lean body mass, with some clinicians targeting 2.0 g/kg for older or more deconditioned populations. For a 75 kg adult with 55 kg lean mass, that is 90 to 110 g per day. Hitting this is not trivial when appetite is suppressed and you can comfortably skip meals. Two weeks of 50 g per day is the start of meaningful lean-mass loss.
A tracker that asks for protein in grams every day is doing more for muscle preservation than the resistance training itself, because most people will lift if they say they will but very few will eat protein on a day they are not hungry without a prompt. miora's daily check includes protein intake by default for users on weight-loss GLP-1 protocols. The muscle-preservation guide walks the protein-plus-training protocol in detail.
Daily weight on a Zepbound cycle moves 1.5 to 3 lbs in either direction on water and stool weight alone. None of this has anything to do with whether the protocol is working. The signal lives in the 7-day or 14-day moving average.
Reasonable rates on a tolerated Zepbound protocol are roughly 0.5 to 1.5% of body weight per month after the first month. Faster than that and the user is usually under-fueled - the muscle loss will show up in DEXA. Slower than that and the protocol may be hitting a stall that warrants investigation: hydration, food quality, sleep, training, or a step change.
The smoothed trend is also the data that determines when to stop titrating. If the rate of loss is acceptable at the current step, there is no reason to escalate just because the schedule says so. The maintenance dose is the lowest dose that produces acceptable loss with acceptable side effects, not the highest dose tolerated.
The daily flow is one text in the evening: 'Zepbound check, day N: nausea / fatigue / GI / hydration oz / protein g / weight if logged?' Typical reply: '2 3 OK 60 102 196.3' or in prose, 'mild nausea, normal energy, GI fine, 60 oz, hit protein, scale at 196.3.'
The injection event is a separate log: 'injected Zepbound 10 mg, right thigh, 7:45 a.m.' miora confirms the dose step, the next planned titration date (or hold date if at ceiling), and notes the rotation - injection sites need to alternate to avoid lipohypertrophy, and most users do not track which site they used last week.
The weekly summary is where the cross-reference happens. A representative week-3 summary at the 10 mg step might read: 'Day-1 nausea averaged 1.8, down from 2.6 at week-1 of this step - curve compressing as expected. Protein hit on six of seven days. Hydration averaged 58 oz; this is the lever. Smoothed weight down 1.4 lbs week-over-week (about 0.7% of body weight). Next titration to 12.5 on schedule and side-effect profile supports the step.' The next prescriber visit starts with that, not with 'I think it is going OK.'
Insurance coverage on Zepbound versus Mounjaro is unstable and the formulary status changes quarterly for many plans. It is common to be switched from one to the other mid-protocol. The compound is identical; the tracking should treat this as a continuation rather than a reset.
What changes when you switch: the brand on the pen, possibly the prescriber, sometimes the prior-authorization paperwork. What does not change: the dose step, the side-effect profile, the side-effect curve compression timeline, the protein and hydration requirements. miora handles a mid-protocol brand switch by updating the label on subsequent doses without restarting the baseline.
The same applies if a user moves from branded Zepbound to compound tirzepatide for cost reasons. The tracking changes from pen-confirmed dose to vial-and-syringe dose math, but the side-effect rubric and the weight trend are continuous. miora handles both formats in the same thread.
The Zepbound prescriber visit benefits from structured data more than most. Flags worth bringing:
Side-effect curve not compressing at a new step by week three. The step may be the ceiling.
Day-1 nausea at 4-out-of-5 for two consecutive cycles at any step. Worth discussing dose hold or step-down.
Smoothed weight loss faster than 2% of body weight per month. Body composition check warranted.
Smoothed weight loss stalled for four weeks at the current step with no obvious amplifier explanation. Worth a titration discussion.
Protein intake below 80 g for two weeks. Muscle-preservation risk.
Resting heart rate up 5+ bpm over two weeks without training-load explanation. Labs worth checking.
Mood drift below baseline for two weeks at stable dose. Anhedonia is the under-reported month-3 signal.
Bringing the chart with the flags lets the prescriber adjust intelligently. miora can export a clinician-ready summary in PDF or shareable text on request.
Two boundaries.
This guide does not recommend Zepbound for any specific person or condition. Zepbound is FDA-approved for chronic weight management in adults with obesity or overweight plus at least one weight-related comorbidity. Whether it is right for you is between you and your prescriber.
The guide also does not promise specific weight-loss outcomes. The average rates reported in the SURMOUNT trials are population averages; individual response varies widely based on dose, adherence, food intake, training, sleep, and dozens of other factors. A good tracker helps you run the protocol you have been prescribed with cleaner data and earlier flags - it does not change the underlying response. This content is for informational purposes only and is not medical advice. Zepbound requires prescription and clinician supervision.
100
